查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827413

癌症疫苗市場按產品類型、配方、給藥途徑、開發​​階段、適應症和最終用戶分類－2025-2032 年全球預測

Cancer Vaccines Market by Product Type, Formulations, Administration Pathway, Development Phase, Indication, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年癌症疫苗市場規模將成長至 150.8 億美元，複合年成長率為 9.84%。

主要市場統計數據
基準年2024年 71.1億美元
預計2025年 77.8億美元
預測年份：2032年 150.8億美元
複合年成長率（%） 9.84%

簡要回顧重塑癌症疫苗開發和相關人員決策的科學、臨床和商業性力量

癌症疫苗領域正處於關鍵的曲折點，這得益於數十年的免疫學研究、分子生物學的進步以及商業性對免疫癌症治療方案的重新燃起的興趣。本執行摘要概述了塑造該領域的核心動態，並闡述了新型抗原的發現、遞送平台和轉化科學如何融合，重新定義惡性腫瘤的治療和預防方法。本引言重點介紹了創新的驅動力、不斷變化的法規以及臨床應用的瓶頸，為後續的深入分析奠定了基礎。

重要的是，這種格局將既定的科學原理與快速的技術迭代相結合，要求相關人員在審視科學突破的同時，也要兼顧製造複雜性、供應鏈韌性和報銷環境等商業現實。展望未來，本報告將採用整合視角，將科學前景與實際執行相結合，幫助決策者優先考慮在短期臨床可行性與長期策略差異化之間取得平衡的投資。

平台成熟度、適應性監管參與和策略聯盟如何從根本上改變發展路徑和競爭優勢的動態

過去幾年，癌症疫苗產業格局經歷了變革性變化，這些變化超越了單一的科學突破，涵蓋了平台演進、監管調整和產業策略調整。首先，核酸平台的成熟加速了原型設計的速度，也讓個人化迭代疫苗設計更加便利。因此，研發人員現在正在尋求將現成組件與個人化新抗原有效載荷相結合的混合策略，從而推動了專案設計和臨床開發時間表的轉變。

同時，製造創新以及經驗豐富的受託製造公司的崛起正在改變生產力計畫，並降低規模化門檻。監管機構早期就願意參與平台特定的終點和自適應試驗設計，這鼓勵了申辦方尋求切實可行的途徑來證明臨床效用。同時，商業策略正在從單一產品轉向以生態系統為中心的方法，將疫苗與伴隨診斷、查核點抑制劑、放射療法和其他療法相結合，以提高療效的持久性。

這種綜合轉變意味著，能夠將快速抗原發現、靈活生產和強大的轉化生物標記計畫結合的組織將擁有越來越大的競爭優勢。因此，夥伴關係和策略聯盟正成為加速研發並在專業合作夥伴之間分散風險的主要手段。

評估 2025 年關稅變化和貿易政策變化將如何重塑整個疫苗生態系統的採購、製造彈性和臨床試驗物流

2025年關稅的實施和貿易政策的調整，使得支持癌症疫苗研發和商業化的全球供應鏈變得錯綜複雜。關稅導致試劑、一次性塑膠和某些生物加工零件的投入成本增加，這改變了籌資策略，並促使申辦者重新評估供應商多元化和近岸外包的選擇。因此，企業必須在成本控制與維護其敏感生技藥品業務所需的高品質、合規供應鏈之間尋找平衡。

此外，關稅影響了臨床試驗材料和臨床實驗藥物的跨境流動，增加了行政管理的複雜性，並可能導致跨國試驗的延誤。因此，臨床試驗贊助者在調整物流計劃，增加緩衝庫存，並儘早與海關和監管相關人員溝通，以最大程度地減少干擾。此外，累積的政策環境正在影響投資者情緒和資本配置決策，尤其是那些依賴國際合作夥伴進行生產和分銷的早期公司。

從策略角度來看，最具韌性的公司正在透過以下方式應對：繪製關鍵供應商圖譜、確定替代投入，並協商長期採購協議。同時，決策者正在評估對區域生產能力和合作聯盟的投資，以分散關稅風險，同時保持疫苗迭代開發所需的靈活性。

解釋多方面的細分，以針對不同適應症和環境的差異化疫苗計畫量身定做處方、臨床策略和護理服務

細分層面的動態揭示了差異化的需求和機遇，為產品策略、臨床設計和上市計劃提供資訊。根據產品類型，該領域分為預防性癌症疫苗和治療性癌症疫苗，每種疫苗都有不同的目標族群、監管途徑和商業性價值提案。預防性疫苗需要廣泛的安全性和縱向監測框架，而治療性疫苗則強調腫瘤特異性免疫抗原性和組合方案，以達到持久的療效。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大使用人工智慧來識別新的癌症疫苗標靶並最佳化配方
  • 增加對新抗原癌症疫苗的投資，加速精準腫瘤學的效益
  • 利用人工智慧和機器學習最佳化癌症疫苗設計和患者選擇
  • 開發旨在誘導更廣泛的抗癌免疫反應的多表位疫苗
  • 癌症疫苗輸送系統的創新提高了疫苗的有效性和患者的依從性
  • 透過協助監管部門核准，促進創新癌症疫苗的商業化
  • 擴大病毒相關癌症的預防性癌症疫苗
  • 利用新抗原標靶化增強免疫反應的個人化癌症疫苗的進展
  • 生技公司之間加強合作加速癌症疫苗研發
  • 擴大預防性癌症疫苗以預防病毒相關惡性腫瘤

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 癌症疫苗市場：依產品類型

  • 預防癌症疫苗
  • 治療性癌症疫苗

第9章 癌症疫苗市場（以劑型）

  • 細胞疫苗
    • 樹突細胞疫苗
    • 癌細胞疫苗
  • 核酸疫苗
    • DNA疫苗
    • RNA疫苗
  • 胜肽/蛋白質疫苗
  • 合成疫苗
  • 基於病毒載體的疫苗

第10章 癌症疫苗市場（依給藥途徑）

  • 肌肉注射
  • 靜脈

第11章癌症疫苗市場（依開發階段）

  • 臨床試驗
  • 第一階段
  • 第二階段
  • 第三階段

第12章 癌症疫苗市場：按適應症

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 黑色素瘤
  • 攝護腺癌

第13章 癌症疫苗市場：依最終用戶

  • 癌症研究所
  • 醫院和診所
  • 專門的癌症治療中心

第14章 癌症疫苗市場：依地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 癌症疫苗市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 16 章：各國癌症疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Amgen Inc.
    • Bayer AG
    • Advaxis Inc.
    • AstraZeneca PLC
    • BioNTech SE
    • Bristol Myers Squibb Company
    • Celldex Therapeutics, Inc.
    • CureVac SE
    • Dynavax Technologies Corporation
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK PLC
    • Helsinn Healthcare SA
    • Inovio Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc
    • JW CreaGene
    • Merck & Co., Inc.
    • Moderna, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Sanpower Group Co., Ltd.
    • Scorpius Holdings, Inc.
    • Serum Institute of India Pvt. Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Vaxine Pty Ltd
Product Code: MRR-434CCDA0514B

The Cancer Vaccines Market is projected to grow by USD 15.08 billion at a CAGR of 9.84% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.11 billion
Estimated Year [2025] USD 7.78 billion
Forecast Year [2032] USD 15.08 billion
CAGR (%) 9.84%

A concise orientation to the scientific, clinical, and commercial forces converging to reshape cancer vaccine development and stakeholder decision-making

The field of cancer vaccines is at a pivotal inflection point driven by decades of immunology research, advances in molecular biology, and renewed commercial interest in immune-based oncology solutions. This executive summary synthesizes core dynamics shaping the sector, framing how novel antigen discovery, delivery platforms, and translational science converge to redefine therapeutic and preventive approaches to malignancies. By clarifying the drivers of innovation, regulatory evolution, and clinical translation bottlenecks, this introduction sets context for the deeper analytical sections that follow.

Importantly, the landscape combines established scientific principles with rapid technological iteration, meaning that incremental improvements in vaccine design can yield outsized clinical and operational benefits. As such, stakeholders must view scientific breakthroughs alongside commercialization realities including manufacturing complexity, supply chain resilience, and reimbursement environments. Moving forward, this report adopts an integrated lens that links scientific promise to practical execution, enabling decision-makers to prioritize investments that balance near-term clinical feasibility with longer-term strategic differentiation.

How platform maturation, adaptive regulatory engagement, and strategic alliances are fundamentally altering development pathways and competitive advantage dynamics

Over the past several years the cancer vaccine landscape has undergone transformative shifts that extend beyond isolated scientific breakthroughs to encompass platform evolution, regulatory recalibration, and strategic industry realignment. First, the maturation of nucleic acid platforms has accelerated iterative vaccine designs that are faster to prototype and easier to personalize. Consequently, developers now pursue hybrid strategies that combine off-the-shelf components with individualized neoantigen payloads, driving a shift in program design and clinical development timelines.

Concurrently, manufacturing innovations and the rise of experienced contract development and manufacturing organizations have altered capacity planning and lowered some barriers to scale. In parallel, regulators have signaled a willingness to engage early on platform-specific endpoints and adaptive trial designs, which has encouraged sponsors to pursue pragmatic pathways to demonstrate clinical benefit. At the same time, commercial strategies have shifted from single-product plays to ecosystem-focused approaches that pair vaccines with companion diagnostics, checkpoint inhibitors, or radiotherapy to enhance response durability.

These combined shifts mean that competitive advantage will increasingly accrue to organizations that can integrate rapid antigen discovery, flexible manufacturing, and robust translational biomarker programs. As a result, partnerships and strategic alliances are becoming a primary vehicle for accelerating development while distributing risk across specialized collaborators.

Assessing how tariff shifts and trade policy changes in 2025 are reshaping procurement, manufacturing resilience, and clinical trial logistics across the vaccine ecosystem

The imposition of tariffs and trade policy adjustments in 2025 introduced a complex overlay on the global supply chains that underpin cancer vaccine research, development, and commercialization. Tariff-driven increases in input costs for reagents, single-use plastics, and certain bioprocessing components have altered procurement strategies and prompted sponsors to re-evaluate supplier diversification and nearshoring options. In turn, organizations must reconcile the tension between cost management and the necessity of maintaining high-quality, compliant supply chains for sensitive biologics work.

Moreover, tariffs have affected cross-border movement of clinical trial materials and investigational products, adding administrative complexity and potential delays in multinational study execution. Consequently, trial sponsors are adjusting logistics planning, expanding buffer stocks, and engaging earlier with customs and regulatory stakeholders to minimize disruption. In addition, the cumulative policy environment has influenced investor sentiment and capital allocation decisions, particularly for early-stage companies that rely on international partnerships for manufacturing or distribution.

From a strategic standpoint, the most resilient organizations respond by mapping critical suppliers, identifying substitute inputs, and negotiating longer-term procurement agreements. At the same time, decision-makers are evaluating investments in regional manufacturing capacity and collaborative consortia that spread tariff exposure while preserving the agility required for iterative vaccine development.

Interpreting multi-dimensional segmentation to align formulation, clinical strategy, and care delivery for differentiated vaccine programs across indications and settings

Segment-level dynamics reveal differentiated needs and opportunities that inform product strategy, clinical design, and go-to-market planning. Based on product type, the field separates into preventive cancer vaccines and therapeutic cancer vaccines, each with distinct target populations, regulatory pathways, and commercial value propositions. Preventive approaches necessitate broad safety and long-term surveillance frameworks, whereas therapeutic vaccines emphasize tumor-specific immunogenicity and combination regimens to achieve durable responses.

Based on formulations, developers are advancing multiple modalities including cell-based vaccines, nucleic acid-based vaccines, peptide and protein constructs, synthetic vaccines, and viral vector systems. Within cell-based approaches, dendritic cell vaccines and tumor cell vaccines offer different manufacturing complexity and personalization trade-offs. Similarly, nucleic acid-based platforms differentiate into DNA vaccines and RNA vaccines, with each presenting unique delivery and stability considerations that affect clinical deployment.

Based on administration pathway, studies and clinical operations focus on intramuscular and intravenous delivery routes, choices that influence patient experience, pharmacokinetics, and site-of-care logistics. Based on development phase, programs span clinical trials across Phase I, Phase II, and Phase III, shaping evidence requirements and regulatory engagement strategies. Based on indication, teams prioritize target malignancies such as breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer, each of which imposes distinct biomarker, endpoint, and competitive considerations. Based on end-user, adoption pathways vary across cancer research institutes, hospitals and clinics, and specialty cancer treatment centers, factors that inform commercialization and reimbursement planning.

Taken together, these segmentation lenses illustrate that no single development path fits all programs; instead, sponsors must align formulation, delivery, and clinical strategy to the indication, patient population, and intended care setting to optimize chances of successful translation.

How regional regulatory nuance, clinical capacity, and manufacturing capabilities across global regions shape development priorities and market entry strategies

Regional dynamics significantly influence development priorities, regulatory engagement, and commercial planning across the cancer vaccine landscape. In the Americas, strong venture capital activity, advanced clinical trial infrastructure, and established biomanufacturing networks support rapid iteration and early human testing. Consequently, sponsors often prioritize first-in-human studies and regulatory interactions in these markets to de-risk science and secure early clinical validation.

In Europe, Middle East & Africa, diverse regulatory frameworks and varying reimbursement pathways require tailored evidence generation strategies, while the region's strong academic networks and collaborative research consortia provide fertile ground for translational science and investigator-initiated trials. Stakeholders operating in this region often engage early with regional regulators and payers to harmonize clinical endpoints and access pathways.

In the Asia-Pacific region, accelerating public and private investment in biotechnology, expanding manufacturing capacity, and growing patient populations create opportunities for large-scale studies and regional manufacturing partnerships. However, developers must navigate heterogeneous regulatory timelines and local clinical practice patterns. Across all regions, successful strategies combine global program design with regional execution plans that account for regulatory nuance, supply chain considerations, and local stakeholder engagement to enable efficient development and market entry.

Evaluating strategic business models, partnership dynamics, and operational capabilities that determine competitive differentiation and partnership appeal in the sector

Company strategies in the cancer vaccine sector reflect a spectrum of models that range from vertically integrated innovators to specialized technology providers and manufacturing partners. Biotech companies pursue differentiated platforms with an emphasis on proprietary antigen discovery engines, while larger pharmaceutical firms are increasingly focused on integrating vaccines into combination regimens that leverage their existing oncology portfolios. Across the ecosystem, strategic collaborations, licensing agreements, and co-development arrangements serve as primary mechanisms to obtain complementary capabilities and accelerate time to clinic.

Notably, contract development and manufacturing organizations play a pivotal role by enabling smaller developers to access GMP-compliant production and scale-up expertise without the capital intensity of building internal capacity. In addition, diagnostic developers and biomarker companies are becoming essential allies, providing the companion tools needed to select patients and measure pharmacodynamic responses. Investors and corporate development teams are therefore evaluating partner fit across technical proficiency, regulatory experience, and cultural alignment to manage program risk.

Ultimately, competitive differentiation will depend on the ability to combine scientific novelty with operational excellence, regulatory foresight, and reimbursement strategy. Companies that can demonstrate reproducible manufacturing, robust translational datasets, and clear paths to payer evidence will command strategic advantage in partnerships and capital markets.

Practical, milestone-driven steps that biopharma leaders can implement to de-risk programs, accelerate clinical translation, and strengthen payer and partner negotiations

Leading organizations must adopt pragmatic, high-impact actions to translate scientific potential into durable clinical and commercial outcomes. First, prioritize platform validation through well-designed translational studies that link mechanistic biomarkers to meaningful clinical endpoints; this approach reduces late-stage attrition and strengthens conversations with regulators and payers. Next, invest in flexible manufacturing arrangements and dual-sourcing strategies to mitigate supply chain risk and respond quickly to iterative program adjustments.

Additionally, pursue strategic collaborations that align scientific synergies with operational needs, such as partnering with diagnostic developers to co-develop companion assays or engaging experienced CDMOs to accelerate GMP manufacturing timelines. Further, adopt adaptive clinical trial designs and real-world evidence collection strategies to generate robust datasets that support both regulatory submissions and payer negotiations. From a commercial perspective, refine value propositions by mapping patient pathways and stakeholder economics to ensure pricing and access strategies reflect clinical differentiation and real-world impact.

Finally, build internal capabilities in regulatory strategy, health economics and outcomes research, and manufacturing science to reduce dependence on external partners and to retain negotiating leverage. By sequencing these actions and establishing clear milestone-based decision gates, leaders can preserve optionality while accelerating programs that demonstrate the highest probability of clinical and commercial success.

A transparent, multi-source research approach combining primary interviews, technical literature, and analytical validation to underpin practical, evidence-based recommendations

This research employs a mixed-methods approach that integrates primary interviews, rigorous secondary research, and analytical triangulation to ensure robust and actionable findings. Primary research included structured interviews with industry executives, clinical investigators, manufacturing experts, and payer advisors to capture real-world perspectives on operational constraints, trial design preferences, and commercial access expectations. These qualitative inputs were synthesized with publicly available regulatory guidance, peer-reviewed literature, and company disclosures to construct a comprehensive understanding of sector dynamics.

Secondary research encompassed literature review, analysis of clinical trial registries, and technical white papers that document platform performance, safety profiles, and biomarker strategies. The methodology also applied comparative analysis across regional regulatory frameworks and supply chain configurations to highlight executional risks and opportunities. Analytical validation steps included cross-checking interview insights against documented trial outcomes and manufacturing case studies, and conducting scenario analysis to explore policy and operational contingencies.

Limitations of the approach are acknowledged; for instance, proprietary internal data from private firms may not be fully accessible, and rapidly evolving trial outcomes can shift competitive positions. Nevertheless, the triangulated methodology provides a defensible basis for strategic recommendations and enables stakeholders to tailor the insights to their specific portfolio and risk appetite.

A synthesis of scientific opportunity and executional requirements that clarifies how leaders must balance innovation, resilience, and strategic partnerships to succeed

In conclusion, cancer vaccines occupy a dynamic intersection of scientific innovation, commercial opportunity, and operational complexity. Advances in platform technologies and translational science have expanded the realm of possibility, but realizing clinical and commercial impact requires disciplined execution across manufacturing, regulatory strategy, and payer engagement. Moreover, trade policy and supply chain considerations are now integral to development planning, motivating sponsors to adopt diversified sourcing and geographically informed manufacturing strategies.

Going forward, organizations that integrate rigorous biomarker-driven program designs with flexible manufacturing and strategic partnerships will be best positioned to navigate the competitive environment. Strategic patience, combined with targeted investments in clinical validation and operational resilience, will enable sponsors to convert scientific promise into patient benefit. Ultimately, the path to success is multifaceted and demands that scientific ambition be matched by pragmatic, well-resourced execution across the entire product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising use of artificial intelligence in identifying novel cancer vaccine targets and optimizing formulations
  • 5.2. Growing investment in neoantigen-based cancer vaccines fueling precision oncology benefits
  • 5.3. Utilization of AI and machine learning for optimizing cancer vaccine design and patient selection
  • 5.4. Development of multi-epitope vaccines designed to elicit broader immune responses against cancer
  • 5.5. Innovations in delivery systems for cancer vaccines increasing efficacy and patient compliance
  • 5.6. Supportive regulatory approvals fueling the commercialization of innovative cancer vaccines
  • 5.7. Expansion of preventive cancer vaccines targeting virus-associated cancers
  • 5.8. Advancements in personalized cancer vaccines leveraging neoantigen targeting enhancing immune response
  • 5.9. Rising collaboration among biotech firms accelerating cancer vaccine research and development
  • 5.10. Expansion of prophylactic cancer vaccines aiming to prevent virus-associated malignancies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Vaccines Market, by Product Type

  • 8.1. Preventive Cancer Vaccines
  • 8.2. Therapeutic Cancer Vaccines

9. Cancer Vaccines Market, by Formulations

  • 9.1. Cell-Based Vaccines
    • 9.1.1. Dendritic Cell Vaccines
    • 9.1.2. Tumor Cell Vaccines
  • 9.2. Nucleic Acid-Based Vaccines
    • 9.2.1. DNA Vaccines
    • 9.2.2. RNA Vaccines
  • 9.3. Peptide/Protein-Based Vaccines
  • 9.4. Synthetic Vaccines
  • 9.5. Viral Vector-Based Vaccines

10. Cancer Vaccines Market, by Administration Pathway

  • 10.1. Intramuscular
  • 10.2. Intravenous

11. Cancer Vaccines Market, by Development Phase

  • 11.1. Clinical Trials
  • 11.2. Phase I
  • 11.3. Phase II
  • 11.4. Phase III

12. Cancer Vaccines Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Colorectal Cancer
  • 12.3. Lung Cancer
  • 12.4. Melanoma
  • 12.5. Prostate Cancer

13. Cancer Vaccines Market, by End-User

  • 13.1. Cancer Research Institutes
  • 13.2. Hospitals & Clinics
  • 13.3. Specialty Cancer Treatment Centers

14. Cancer Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Amgen Inc.
    • 17.3.2. Bayer AG
    • 17.3.3. Advaxis Inc.
    • 17.3.4. AstraZeneca PLC
    • 17.3.5. BioNTech SE
    • 17.3.6. Bristol Myers Squibb Company
    • 17.3.7. Celldex Therapeutics, Inc.
    • 17.3.8. CureVac SE
    • 17.3.9. Dynavax Technologies Corporation
    • 17.3.10. Eli Lilly and Company
    • 17.3.11. F. Hoffmann-La Roche AG
    • 17.3.12. GSK PLC
    • 17.3.13. Helsinn Healthcare SA
    • 17.3.14. Inovio Pharmaceuticals, Inc.
    • 17.3.15. Johnson & Johnson Services, Inc
    • 17.3.16. JW CreaGene
    • 17.3.17. Merck & Co., Inc.
    • 17.3.18. Moderna, Inc.
    • 17.3.19. Pfizer Inc.
    • 17.3.20. Sanofi SA
    • 17.3.21. Sanpower Group Co., Ltd.
    • 17.3.22. Scorpius Holdings, Inc.
    • 17.3.23. Serum Institute of India Pvt. Ltd.
    • 17.3.24. Sun Pharmaceutical Industries Ltd.
    • 17.3.25. Vaxine Pty Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CANCER VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CANCER VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN C